Bishop et al., “Novel Tricyclic Inhibitors of Farnesyl Protein Transferase”, The Journal of Biological Chemistry 270:30611-30618, 1995. |
Bhide et al., “Rational Design of Potent Carboxylic Acid Based Bisubstrate Inhibitors of Ras Farnesyl Protein Transferase” Bioorganic & Medicinal Chemistry Letters 4:2107-2112, 1994. |
Buss et al., “Farnesyl Transferase Inhibitors: The Successes and Surprises of a New Class of Potential Cancer Chemotherapeutics”, Chemistry & Biology 2:787-791, Dec. 1995. |
Clerc et al., “Constrained Analogs of KCVFM With Improved Inhibitory Properties Against Farnesyl Transferase” Biorganic & Medicinal Chemistry Letters 16:1779-1784, 1995. |
deSolmes et al., “Pseudodipeptide Inhibitors of Protein Farnesyltransferase”, J. Med. Chem, 38:3967-3971, 1995. |
Garcia et al., “Peptidomimetic Inhibitors of Ras Farnesylation and Function in Whole Cells”, The Journal of Biology Chemistry vol. 268, No. 25, pp. 18415-18418, 1993. |
Graham et al., “Pseudopeptide Inhibitors of Ras Farnesyl-Protein Transferase”, J. Med. Chem. 37:725-732, 1994. |
Gibbs et al., “Farnesyltransferase Inhibitors: Ras Research Yields a Potential Cancer Therapeutic”, Cell 77:175-1 Apr. 22, 1994. |
Harrington et al., “Cysteine and Methionine Linked by Carbon Pseudopeptides Inhibit Farnesyl Transferase”, Bioo & Medicinal Chemistry Letters vol. 4, No. 23, pp. 2775-2780. 1994. |
Hunt et al., “Potent, Cell Active, Non-Thiol Tetrapeptide Inhibitors of Farnesyltransferase”, J. Med. Chem. 39:353-1996. |
James et al., “Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation in Animal Cells”, Science 260:1937-1942, Jun. 25, 1993. |
James et al., “Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance Benzodiazepine Peptidomimetic in Vitro”, The Journal of Biological Chem. vol. 270, No. 11, pp. 6221-6226, 1995. |
Koblan et al., “NMR Studies of Novel Inhibitors Bound to Farnesyl-Protein Transferase”, Protein Science 4:681-688. |
Kohl et al., “Development of Inhibitors of Protein Farnesylation as Potential Chemotherapeutic Agents”, Journal of Cellular Biochemistry 22:145-150, 1995. |
Kohl et al., “Inhibition of Farnesyl transferase Induces Regression of Mammary and Salivary Carcinomas in Ras Transgenic Mice”, Nature Medicine vol. 1, No. 8, pp. 792-797, 1995. |
Kohl et al., “Inhibition of Ras Function in Vitro and in Vivo Using Inhibitors of Farnesyl-Protein Transferase”, Meth Enzymology 255:378-386, 1989. |
Kohl et al., “Selective Inhibition of ras-Dependent Transformation by a Farnesyltransferase Inhibitor”, Science 260:1934-1937, Jun. 25, 1993. |
Leftheris et al., “Development of Highly Potent Inhibitors of Ras Farnesyltransferase Possessing Cellular and in Vivo Activity”, J. Med. Chem. vol. 39, No. 1, pp. 224-236, 1996. |
Lerner et al., “Rase CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signalling by Inducing Cytopia Accumulation of Inactive Ras-Raf Complexes”, The J. of Biological Chem. vol. 270, No. 45, pp. 26802-26806, 1995. |
Li et al., Total Synthesis of the Antitumor Depsipeptide FR-901, 228, J. Am. Chem. Soc. vol. 118, No. 30, pp. 7237-1996. |
Nagasu et al., “Inhibition of Human Tumor Xenograft Growth by Treatment with the Farnesyl Transferase Inhibitor: 8956”, Cancer Research 55:5310-5314, Nov. 15, 1995. |
Nigam et al., “Potent Inhibition of Human Tumor p21ras Farnesyltransferase by A1A2-lacking p21ras . . . ”, The Journal Biological Chemistry vol. 268, No. 28, pp. 20695-20698, 1993. |
Qian et al., Design and Structural Requirements of Potent Peptidomimetic Inhiboitors of p21 ras Farnesyltransferase The Journal of Biological Chemistry vol. 269, No. 17, pp. 12410-124213, 1994. |
Qian et al., “Design and Synthesis of Non-Peptide Ras CAAX Mimetics as Potent Farnesyltransferase Inhibitors” J. Chem. vol. 39, No. 1, pp. 217-223, 1996. |
Patel et al., “Phenol Based Tripeptide Inhibitors of Ras Farnesyl Protein Transferase”, Bioorganic & Medicinal Chem Letters vol. 4, No. 15 pp. 1883-1888, 1994. |
Reiss et al., “Sequence Requirement for Peptide Recognition by Rat Brain p21ras Protein Farnesyltransferase”, Proc Acad. Sci. USA 88: 732-736, 1991. |
Sepp-Lorenzino et al., “A Peptidomimetic Inhibitor of Farnesyl:Protein Transferase Blocks the Anchorage-Dependent and-Independent Growth of Human Tumor Cell Lines”, Cancer Research 55:5302-5309, 1995. |
Shigematsu et al., “FR901228, A Novel Antitumor Bicyclic Depsipeptide Produced by Chromobacterium violaceum968 II Structure Determination”, The Journal of Antibiotics vol. 47, No. 3., pp. 311-314, 1994. |
Singh et al., “Fusidienol: A Novel Inhibitor of Ras Farnesyl-Protein Transferase from Fusidium griseum”, Tetrahed Letters,, vol. 35, No. 27, pp. 4693-4696, 1994. |
Ueda et al., “FR901228, A Novel Antitumor Bicyclic Depsipeptide Produced by Chromobacterium violaceumNo. 968 Taxonomy, Fermentation Isolation . . . ” The Journal of Antibiotics vol. 47, No. 3, pp-301-310, 1994. |
Ueda et al., “FR901228, A Novel Antitumor Bicyclic Depsipeptide Produced by Chromobacterium violaceumNo. 968. Antitumor Activities on Experimental Tumors in Mice”, The Journal of Antibiotics vol. 47, pp. 315-323, 1994. |
Vogt et al., “A Non-Peptide Mimetic of Ras-CAAX: Selective Inhibition of Farnesyltransferase and Ras Processing”, Journal of Biological Chemistry, vol. 270, No. 2, pp. 660-664, 1995. |
Williams et al., “2-Substituted Piperazines as Constrained Amino Acids. Application to the Synthesis of Potent Non Carboxylic Acid Inhibitors of Farnesyltransferase”, J. of Medicinal Chemistry, vol. 39, No. 7, pp. 1345-1348, 1996. |
Byk et al., “Local Constrained Shifty Pseudopeptides Inhibitors of Ras-Farnesyl Transferase”, Bioorganic & Medicin: Chemistry Letters vol. 5, No. 22, pp. 2677-2682, 1995. |
Sugawara et al., Structure of Malformin A2, Reinvestigation of Phytotoxic Metabolites Produced by Aspergillus Nige Tetrahedron Letters vol. 31, No. 30, pp. 4337-4340, 1990. |